Alar Pharmaceuticals is making significant progress across its pipeline, with multiple programs advancing in parallel. Its lead candidate ALA-1000, licensed to Indivior, is expected to enter Phase 3 clinical trials by the first quarter of next year at the latest, potentially bringing in a new wave of milestone payments. ALA-1000 is also being evaluated in a 12-dog study for pet use; about 10 dogs have been enrolled so far, with a treatment success rate of 73%, consistent with expectations. The study is slated for completion this year.
Read more
